Takeda Pharmaceutical Company Limited (TKDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has a cash flow conversion efficiency ratio of 0.049x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€373.25 Billion ≈ $436.37 Billion USD) by net assets (€7.64 Trillion ≈ $8.94 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Takeda Pharmaceutical Company Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Takeda Pharmaceutical Company Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Takeda Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CTBC Financial Holding Co Ltd
TW:2891
|
0.246x |
|
East Money Information Co Ltd
SHE:300059
|
-0.037x |
|
Itaú Unibanco Holding S.A.
SA:ITUB3
|
-0.024x |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
0.080x |
|
Ambev S.A.
F:AMNA
|
0.149x |
|
LG Electronics Inc
KO:066570
|
0.061x |
|
Doosan Heavy Ind. & Const.
KO:034020
|
0.116x |
|
STANDARD CHART.UNSP.ADR/2
F:STD0
|
N/A |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Company Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Takeda Pharmaceutical Company Limited (TKDA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €6.94 Trillion ≈ $8.11 Trillion |
€1.06 Trillion ≈ $1.24 Trillion |
0.152x | +54.77% |
| 2024-03-31 | €7.27 Trillion ≈ $8.50 Trillion |
€716.34 Billion ≈ $837.48 Billion |
0.098x | -35.96% |
| 2023-03-31 | €6.35 Trillion ≈ $7.43 Trillion |
€977.16 Billion ≈ $1.14 Trillion |
0.154x | -22.18% |
| 2022-03-31 | €5.68 Trillion ≈ $6.64 Trillion |
€1.12 Trillion ≈ $1.31 Trillion |
0.198x | +1.20% |
| 2021-03-31 | €5.18 Trillion ≈ $6.05 Trillion |
€1.01 Trillion ≈ $1.18 Trillion |
0.195x | +37.83% |
| 2020-03-31 | €4.73 Trillion ≈ $5.53 Trillion |
€669.75 Billion ≈ $783.01 Billion |
0.142x | +122.70% |
| 2019-03-31 | €5.16 Trillion ≈ $6.04 Trillion |
€328.48 Billion ≈ $384.03 Billion |
0.064x | -66.04% |
| 2018-03-31 | €2.02 Trillion ≈ $2.36 Trillion |
€377.85 Billion ≈ $441.75 Billion |
0.187x | +39.67% |
| 2017-03-31 | €1.95 Trillion ≈ $2.28 Trillion |
€261.36 Billion ≈ $305.56 Billion |
0.134x | -- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more